natgillin/translations-raw huggingface dataset:
• Not known (frequency cannot be estimated from the available data) 
• Nepoznato (učestalost se ne može procijeniti iz dostupnih podataka)
The frequency of possible side effects listed below is defined using the following convention: 
Učestalost niže navedenih mogućih nuspojava definirana je koristeći sljedeće pravilo:
Altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive. 
Promijenjen ili povećan seksualni interes i ponašanje koje je značajno zabrinjavajuće za Vas ili druge, primjerice povećan seksualni nagon.
This leaflet was last revised in <{MM/YYYY}><{month YYYY}>. 
Uputa je zadnji puta revidirana u <{MM/GGGG}><{mjesec GGGG}>.
Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms. 
Obavijestite svog liječnika ako iskusite ovakvo ponašanje; s njim ćete razgovarati o načinima kako kontrolirati ili smanjiti simptome.
• abnormal dreams 
• abnormalni snovi
The effect was evident, although its magnitude was modest in this patient population with mild disease. 
Učinak je bio očit, unatoč tome što je njegov razmjer bio skroman u ovoj populaciji bolesnika s blagom bolešću.
Caution should be exercised when prescribing to pregnant women. 
Nužan je oprez kod propisivanja trudnicama.
Rasagiline is not recommended for use in children and adolescents due to lack of data on safety and efficacy. 
Primjena razagilina ne preporučuje se u djece i adolescenata zbog nedostatka podataka o sigurnosti i djelotvornosti.
The recommended dose is 1 tablet of 1 mg taken by mouth once daily. 
Preporučena doza je 1 tableta od 1 mg uzeta na usta jedanput dnevno.
Any suspicious skin lesion should be evaluated by a specialist. 
Svako sumnjivo oštećenje kože mora se pregledati kod specijalista.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without prescription or if you are smoking or intend to stop smoking. 
Obavijestite svog liječnika ili ljekarnika ako uzimate ili ste nedavno uzimali ili biste mogli uzimati bilo koje druge lijekove, uključujući i one koje ste nabavili bez recepta, ili ako pušite ili namjeravate prestati pušiti.
There was a significant and beneficial effect in quality of life (as assessed by PD-QUALIF scale). 
Učinak na kvalitetu života bio je značajan i koristan (procijenjeno PD-QUALIF ljestvicom).
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: 
Za sve informacije o ovom lijeku obratite se lokalnom predstavniku nositelja odobrenja za stavljanje u promet gotovog lijeka:
Less than 1% of rasagiline is excreted as unchanged product in urine. 
Manje od 1% razagilina se izlučuje nepromijenjeno u urinu.
Not applicable. 
Nije primjenjivo
Elderly No change in dose is required for elderly patients. 
Nije potrebna promjena doze kod starijih bolesnika.
No studies on the effects on the ability to drive and use machines have been performed. 
Nisu provedena ispitivanja o učincima na sposobnost upravljanja vozilima i strojevima.
H-2900 Komárom Hungary. 
H-2900 Komárom Mađarska.
Patients should be regularly monitored for the development of impulse control disorders. 
Bolesnike se mora redovito nadzirati za razvoj poremećaja kontrole impulsa.
• allergy 
• alergija
Dopamine is a chemical in the brain involved in movement control. 
Dopamin je kemijska tvar u mozgu koja je uključena u kontrolu pokreta.
Patients should be cautioned about operating hazardous machines, including motor vehicles, until they are reasonably certain that Rasagiline does not affect them adversely. 
Bolesnici trebaju biti oprezni pri upravljanju opasnim strojevima, uključujući motorna vozila, dok nisu dovoljno sigurni da Rasagiline na njih ne utječe štetno.
If you take more Rasagiline Mylan than you should If you think that you may have taken too many Rasagiline Mylan tablets, contact your doctor or pharmacist immediately. 
Ako uzmete više lijeka Rasagiline Mylan nego što ste trebali Ako mislite da ste možda uzeli previše Rasagiline Mylan tableta, odmah se obratite svom liječniku ili ljekarniku.
• Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached 
• uoči svake izmjene sustava za upravljanje rizikom, a naročito kada je ta izmjena rezultat primitka novih informacija koje mogu voditi ka značajnim izmjenama omjera korist/rizik, odnosno kada je omjer korist/rizik rezultat ostvarenja nekog važnog cilja (u smislu farmakovigilancije ili smanjenja rizika).
CARTON FOR BLISTER PACK 
KUTIJA ZA BLISTER PAKIRANJE
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking any medicine. 
Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku ili ljekarniku za savjet prije nego uzmete bilo koji lijek.
During the clinical development program, the occurrence of cases of melanoma prompted the consideration of a possible association with rasagiline. 
Tijekom programa kliničkog razvoja, pojava slučajeva melanoma potaknula je razmatranja o mogućoj povezanosti s razagilinom.
• low blood pressure when rising to a standing position with symptoms like dizziness/light 
• nizak krvni tlak pri ustajanju u stojeći položaj sa simptomima kao što su omaglica/ošamućenost
Rasagiline is rapidly absorbed, reaching peak plasma concentration (Cmax) in approximately 0.5 hours. 
Razagilin se brzo apsorbira, dosežući vršnu koncentraciju u plazmi (Cmax) za približno 0,5 sati.
Ask your doctor for advice prior to driving or using machines. 
Posavjetujte se sa svojim liječnikom prije upravljanja vozilima ili strojevima.
Rasagiline is administered orally, at a dose of 1 mg once daily with or without levodopa. 
Razagilin se primjenjuje peroralno, u dozi od 1 mg jednom dnevno, sa ili bez levodope.
Rasagiline Mylan is used for the treatment of Parkinson's disease. 
Rasagiline Mylan se primjenjuje za liječenje Parkinsonove bolesti.
It can be used together with or without levodopa (another medicine that is used to treat Parkinson's disease). 
Može se primjeniti zajedno s levodopom ili bez levodope (drugi lijek koji se primjenjuje za liječenje Parkinsonove bolesti).
Adverse events were mild or moderate and not related to rasagiline treatment. 
Štetni događaji bili su blagi ili umjereni i nisu bili povezani s liječenjem razagilinom.
Animals studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). 
Ispitivanja na životinjama ne ukazuju na izravne ili neizravne štetne učinke na trudnoću, embrionalni/fetalni razvoj, porod ili postnatalni razvoj (vidjeti dio 5.3).
The mean volume of distribution following a single intravenous dose of rasagiline is 243 l. 
Distribucija Srednji volumen distribucije nakon jedne intravenske doze razagilina je 243 l.
Rasagiline Mylan helps to increase and sustain levels of dopamine in the brain. 
Rasagiline Mylan pomaže u povećavanju i održavanju razina dopamina u mozgu.
In addition, skin cancer was reported in around 1% of patients in the placebo controlled clinical trials. 
Dodatno, rak kože je bio prijavljen u oko 1 % bolesnika u placebo kontroliranim kliničkim ispitivanjima.
Pharmacotherapeutic group: Anti-Parkinson drugs, Monoamine oxidase-B inhibitors, ATC code: N04BD02 
Farmakoterapijska skupina: Antiparkinsonici, inhibitori monoaminooksidaze B, ATK oznaka: N04BD02
In case of overdose, patients should be monitored and the appropriate symptomatic and supportive therapy instituted. 
U slučaju predoziranja, bolesnike se mora nadzirati te započeti odgovarajuće simptomatsko i suportivno liječenje.
• numbness and muscle weakness of the hand (carpal tunnel syndrome) 
• utrnulost i slabost mišića ruke (sindrom karpalnog tunela)
Blister packs of 7, 10, 28, 30, 100 or 112 tablets PVC/PVDC/Al. 
Blister pakiranja od 7, 10, 28, 30, 100 ili 112 tableta PVC/PVDC/Al.
• difficulty in muscular coordination (balance disorder) 
• poteškoće u mišićnoj koordinaciji (poremećaj ravnoteže)
The following side effects have been reported in placebo controlled clinical trials: 
Sljedeće nuspojave su prijavljene u placebo kontroliranim kliničkim ispitivanjima:
With Parkinson's disease, there is a loss of cells that produce dopamine in the brain. 
Kod Parkinsonove bolesti postoji gubitak stanica koje proizvode dopamin u mozgu.
Rasagiline did not present genotoxic potential in vivo and in several in vitro systems using bacteria or hepatocytes. 
Razagilin nije pokazao genotoksični potencijal in vivo te u nekoliko in vitro sustava korištenjem bakterija ili hepatocita.
These symptoms may resemble those observed with non-selective MAO inhibitors. 
Ovi simptomi mogu nalikovati na one opažene kod neselektivnih MAO inhibitora.
These results indicate that rasagiline's therapeutic concentrations are unlikely to cause any clinically significant interference with substrates of these enzymes. 
Ovi rezultati indiciraju da nije vjerojatno da terapijske koncentracije razagilina prouzročuju bilo kakvu klinički značajnu interferenciju sa supstratima ovih enzima.
In both studies, the primary measure of efficacy was the change from baseline to treatment period in the mean number of hours that were spent in the “OFF” state during the day (determined from “24-hour” home diaries completed for 3 days prior to each of the assessment visits). 
U oba je ispitivanja primarna mjera djelotvornosti bila promjena u srednjem broju sati provedenih u „OFF“ stanju tijekom dana (određivano iz „24-satnih“ kućnih dnevnika popunjavanih tijekom 3 dana prije svakog posjeta procjene) od početne vrijednosti do razdoblja liječenja.
Parkinson's disease is associated with symptoms of hallucinations and confusion. 
Parkinsonova bolest je povezana sa simptomima halucinacija i konfuzije.
There was also a statistically significant improvement over placebo with the rasagiline 0.5 mg group, yet the magnitude of improvement was lower. 
Također je postojalo i statistički značajno poboljšanje u razagilin 0,5 mg skupini u usporedbi s placebom, iako je razmjer poboljšanja bio manji.
• abnormal results of blood tests (leucopenia) 
• abnormalni rezultati krvnih testova (leukopenija)
Overdose can be associated with significant inhibition of both MAO-A and MAO-B. 
Predoziranje može biti povezano sa značajnom inhibicijom MAO-A i MAO-B.
Hypersensitivity to the active substance or to any of the excipients (listed in section 6.1). 
Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari (navedene u dijelu 6.1).
There have been reports of hypotensive effects when rasagiline is taken concomitantly with levodopa. 
Bilo je prijava hipotenzivnih učinaka kada je razagilin uziman istodobno s levodopom.
Decreasing the dose of levodopa may ameliorate this side effect. 
Smanjenje doze levodope može ublažiti ovu nuspojavu.
In a single-dose study healthy volunteers received 20 mg/day and in a ten-day study healthy volunteers received 10 mg/day. 
U ispitivanju s jednokratnom primjenom lijeka zdravi dobrovoljci su primili 20 mg/dan, a u desetodnevnom ispitivanju su primali 10 mg/dan.
Patients with Parkinson's disease are particularly vulnerable to the adverse effects of hypotension due to existing gait issues. 
Bolesnici s Parkinsonovom bolesti su posebno osjetljivi na nepovoljne učinke hipotenzije zbog postojećih problema s hodanjem.
There were no cases of serotonin syndrome in the rasagiline clinical program in which 115 patients were exposed concomitantly to rasagiline and tricyclics and 141 patients were exposed to rasagiline and SSRIs/ SNRIs. 
Nije bilo slučajeva serotoninskog sindroma u kliničkom programu s razagilinom u kojem je 115 bolesnika istodobno bilo izloženo razagilinu i triciklicima, a 141 bolesnik bio je izložen razagilinu i SSRI-ima/SNRI-ima.
The metabolism of rasagiline proceeds through two main pathways: N-dealkylation and/or hydroxylation to yield: 1-Aminoindan, 3-hydroxy-N-propargyl-1 aminoindan and 3-hydroxy-1-aminoindan. 
Metabolizam razagilina se odvija kroz dva glavna puta: N-dealkilacijom i/ili hidroksilacijom te nastaju: 1-aminoindan, 3-hidroksi-N-propargil-1 aminoindan i 3-hidroksi-1 aminoindan.
Take the Rasagiline Mylan carton with you to show the doctor or pharmacist. 
Ponesite sa sobom Rasagiline Mylan kutiju da pokažete svom liječniku ili ljekarniku.
There have been cases of patients who, while taking one or more medications for the treatment of Parkinson's disease, were unable to resist the impulse, drive or temptation to perform an action that could be harmful to themselves or others. 
Zabilježeni su slučajevi bolesnika koji se, tijekom uzimanja jednog ili više lijekova za liječenje Parkinsonove bolesti, nisu mogli oduprijeti nagonu ili iskušenju da izvode određenu radnju koja bi mogla biti škodljiva za njih same ili za druge.
The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagiline's beneficial effects seen in models of dopaminergic motor dysfunction. 
Povišena razina dopamina i posljedična povećana dopaminergička aktivnost vjerojatno posreduju korisne učinke razagilina viđene u modelima dopaminergičke motorne disfunkcije.
A similar pattern of impulse control disorders has been reported post-marketing with rasagiline, which also included compulsions, obsessive thoughts and impulsive behaviour (see section 4.4). 
U postmarketinškom razdoblju je prijavljen sličan model poremećaja kontrole impulsa sa razagilinom, što je također uključivalo kompulzije, opsesivne misli i impulzivno ponašanje (vidjeti dio 4.4).
The absolute bioavailability of a single rasagiline dose is about 36%. 
Apsolutna bioraspoloživost pojedinačne doze razagilina je oko 36%.
Tell your doctor if you or your family/carer notices that you are developing unusual behaviours where you cannot resist the impulse, urges or cravings to carry out certain harmful or detrimental activities to yourself or others. 
Vašeg liječnika ako Vi ili Vaša obitelj/skrbnik primijetite da razvijate neuobičajeno ponašanje u smislu da se ne možete oduprijeti nagonu, potrebi ili žudnji za obavljanjem određenih aktivnosti, škodljivih ili loših za Vas ili druge.
Rasagiline undergoes almost complete biotransformation in the liver prior to excretion. 
Razagilin se gotovo potpuno biotransformira u jetri prije izlučivanja.
In the rasagiline clinical program overall, 1,361 patients were treated with rasagiline for 3,076.4 patient years. 
U kliničkom programu s razagilinom je ukupno 1361 bolesnik bio liječen razagilinom kroz 3076,4 bolesničkih godina.
Children and adolescents Rasagiline Mylan is not recommended for use under the age of 18. 
Ne preporučuje se primjena lijeka Rasagiline Mylan u djece mlađe od 18 godina.
117, Allée des Parcs, 69800 Saint-Priest France 
117, Allée des Parcs, 69800 Saint-Priest Francuska
Rasagiline was not carcinogenic in rats at systemic exposure, 84-339 times the expected plasma exposures in humans at 1 mg/day. 
Razagilin nije bio kancerogen u štakora pri sistemskoj ekspoziciji 84-339 puta većoj od očekivane plazmatske ekspozicije u ljudi pri dozi od 1 mg/dan.
Thus, potent CYP1A2 inhibitors may alter rasagiline plasma levels and should be administered with caution. 
Prema tome, potentni CYP1A2 inhibitori mogu promijeniti razine razagilina u plazmi i moraju se primjenjivati s oprezom.
These are called impulse control disorders. 
Ovo se zove poremećaj kontrole impulsa.
Rasagiline was shown to be a potent, irreversible MAO-B selective inhibitor, which may cause an increase in extracellular levels of dopamine in the striatum. 
Pokazalo se da je razagilin potentan, ireverzibilan MAO-B selektivni inhibitor koji može prouzročiti povećanje izvanstanične razine dopamina u strijatumu.
Impulse control disorders 
Poremećaji kontrole impulsa
Since rasagiline potentiates the effects of levodopa, the adverse effects of levodopa may be increased and pre-existing dyskinesia exacerbated. 
Budući da razagilin pojačava učinke levodope, nuspojave levodope mogu se povećati i već postojeća diskinezija pogoršati.
Experimental data indicated that rasagiline inhibits prolactin secretion and thus, may inhibit lactation. 
Eksperimentalni podaci pokazuju da razagilin inhibira sekreciju prolaktina i prema tome, može inhibirati laktaciju.
Therefore, in view of the MAO inhibitory activity of rasagiline, antidepressants should be administered with caution. 
Stoga se, s obzirom na MAO inhibitornu aktivnost razagilina, antidepresivi moraju primjenjivati s oprezom.
117, Allée des Parcs 69800 Saint-Priest France 
117, Allée des Parcs 69800 Saint-Priest Francuska
Food does not affect the Tmax of rasagiline, although Cmax and exposure (AUC) are decreased by approximately 60% and 20%, respectively, when the medicinal product is taken with a high fat meal. 
Hrana ne utječe na Tmax razagilina, iako je Cmax smanjen za približno 60%, a izloženost (AUC) za približno 20% kada se lijek uzima s obrokom s visokim udjelom masnoća.
1-Aminoindan is an active major metabolite and it is not a MAO-B inhibitor. 
Aktivni glavni metabolit je 1-aminoindan koji nije MAO-B inhibitor.
Tyramine/rasagiline interaction: Results of five tyramine challenge studies (in volunteers and PD patients), together with results of home monitoring of blood pressure after meals (of 464 patients treated with 0.5 or 1 mg/day of rasagiline or placebo as adjunct therapy to levodopa for six months without tyramine restrictions), and the fact that there were no reports of tyramine/rasagiline interaction in clinical studies conducted without tyramine restriction, indicate that rasagiline can be used safely without dietary tyramine restrictions. 
Tiramin/razagilin interakcija: Rezultati iz pet ispitivanja izloženosti tiraminu (u dobrovoljaca i bolesnika s PB), zajedno s rezultatima kućnog nadziranja krvnog tlaka nakon obroka (464 bolesnika liječenih s 0,5 ili 1 mg/dan razagilina ili placebom kao dodatnom terapijom levodopi kroz šest mjeseci bez restrikcija tiramina) i činjenicom da nije bilo prijava tiramin/razagilin interakcija u kliničkim ispitivanjima provedenim bez restrikcije tiramina, upućuju na to da se razagilin može primijenjivati sigurno bez dijetalnih restrikcija tiramina.
• chest pain (angina pectoris) 
• bol u prsima (angina pektoris)
Rasagiline Mylan is indicated for the treatment of idiopathic Parkinson's disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations. 
Rasagiline Mylan je indiciran za liječenje idiopatske Parkinsonove bolesti (PB) kao monoterapija (bez levodope) ili kao dodatna terapija (s levodopom) u bolesnika s fluktuacijama prilikom isteka doze.
Impulse control disorders (ICDs) can occur in patients treated with dopamine agonists and/or dopaminergic treatments. 
Poremećaji kontrole impulsa se mogu pojaviti kod bolesnika liječenih agonistima dopamina i/ili dopaminergičkim lijekovima.
• decreased weight 
• smanjenje tjelesne težine
The use of Rasagiline Mylan together with the antidepressants containing fluoxetine or fluvoxamine should be avoided. 
Istodobna primjena lijeka Rasagiline Mylan s antidepresivima koji sadrže fluoksetin ili fluvoksamin mora se izbjegavati.
Manufacturer Mylan Hungary Kft, Mylan utca 1 
Proizvođač Mylan Hungary Kft, Mylan utca 1
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 
UVJETI ILI OGRANIČENJA VEZANA UZ OPSKRBU I UPORABU LIJEKA
EU/1/16/1090/001 (7 tablets - oPA/alu/PVC/alu) EU/1/16/1090/002 (10 tablets - oPA/alu/PVC/alu) EU/1/16/1090/003 (28 tablets - oPA/alu/PVC/alu) EU/1/16/1090/004 (30 tablets - oPA/alu/PVC/alu) EU/1/16/1090/005 (100 tablets - oPA/alu/PVC/alu) EU/1/16/1090/006 (112 tablets - oPA/alu/PVC/alu) EU/1/16/1090/007 (7 tablets - PVC/PVDC/alu) EU/1/16/1090/008 (10 tablets - PVC/PVDC/alu) EU/1/16/1090/009 (28 tablets - PVC/PVDC/alu) EU/1/16/1090/010 (30 tablets - PVC/PVDC/alu) EU/1/16/1090/011 (100 tablets - PVC/PVDC/alu) EU/1/16/1090/012 (112 tablets - PVC/PVDC/alu) EU/1/16/1090/013 (7 tablets - PVC/PVDC/alu) EU/1/16/1090/014 (10 tablets - PVC/PVDC/alu) EU/1/16/1090/015 (28 tablets - PVC/PVDC/alu) EU/1/16/1090/016 (30 tablets - PVC/PVDC/alu) EU/1/16/1090/017 (100 tablets - PVC/PVDC/alu) EU/1/16/1090/018 (112 tablets - PVC/PVDC/alu) 
EU/1/16/1090/001 (7 tableta - OPA/Al/PVC/Al) EU/1/16/1090/002 (10 tableta - OPA/Al/PVC/Al) EU/1/16/1090/003 (28 tableta - OPA/Al/PVC/Al) EU/1/16/1090/004 (30 tableta - OPA/Al/PVC/Al) EU/1/16/1090/005 (100 tableta - OPA/Al/PVC/Al) EU/1/16/1090/006 (112 tableta - OPA/Al/PVC/Al) EU/1/16/1090/007 (7 tableta - PVC/PVDC/Al) EU/1/16/1090/008 (10 tableta - PVC/PVDC/Al) EU/1/16/1090/009 (28 tableta - PVC/PVDC/Al) EU/1/16/1090/010 (30 tableta - PVC/PVDC/Al) EU/1/16/1090/011 (100 tableta - PVC/PVDC/Al) EU/1/16/1090/012 (112 tableta - PVC/PVDC/Al) EU/1/16/1090/013 (7 x 1 tableta - PVC/PVDC/Al) EU/1/16/1090/014 (10 x 1 tableta - PVC/PVDC/Al) EU/1/16/1090/015 (28 x 1 tableta - PVC/PVDC/Al) EU/1/16/1090/016 (30 x 1 tableta - PVC/PVDC/Al) EU/1/16/1090/017 (100 x 1 tableta - PVC/PVDC/Al) EU/1/16/1090/018 (112 x 1 tableta - PVC/PVDC/Al)
C-labelled rasagiline, elimination occurred primarily via urine (62.6%) and secondarily via faeces (21.8%), with a total recovery of 84.4% of the dose over a period of 38 days. 
Nakon peroralne primjene 14C-označenog razagilina, eliminacija se primarno odvija urinom (62,6%), a sekundarno putem fecesa (21,8%), s potpunim izlučivanjem 84,4% doze lijeka tijekom razdoblja od 38 dana.
Rasagiline Mylan with food and drink Rasagiline Mylan may be taken with or without food. 
Rasagiline Mylan s hranom i pićem Rasagiline Mylan se može uzimati sa ili bez hrane.
What Rasagiline Mylan is and what it is used for 2. 
Što je Rasagiline Mylan i za što se koristi 2.
Adverse reactions are ranked under headings of frequency using the following conventions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000). 
Nuspojave su poredane prema učestalosti javljanja koristeći sljedeće pravilo: vrlo često (≥ 1/10), često (≥ 1/100 do < 1/10), manje često (≥ 1/1000 do < 1/100), rijetko (≥ 1/10 000 do < 1/1000), vrlo rijetko
In mice, increased incidences of combined bronchiolar/alveolar adenoma and/or carcinoma were observed at systemic exposures, 144-213-times the expected plasma exposure in humans at 1 mg/day. 
U miševa je opažena povećana incidencija kombiniranih bronhiolarnih/alveolarnih adenoma i/ili karcinoma pri sistemskim ekspozicijama 144-213 puta većim od očekivane plazmatske ekspozicije u ljudi pri dozi od 1 mg/dan.
Characteristics in patients 
Osobitosti kod bolesnika
There are a number of known interactions between non-selective MAO inhibitors and other medicinal products. 
Poznate su brojne interakcije između neselektivnih MAO inhibitora i drugih lijekova.
Do not use this medicine after the expiry date which is stated on the carton or blister after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji ili blisteru iza „Rok valjanosti“.
In the presence of metabolite activation rasagiline induced an increase of chromosomal aberrations at concentrations with excessive cytotoxicity which are unattainable at the clinical conditions of use. 
Prilikom aktivacije metabolita razagilin je inducirao porast kromosomskih aberacija u koncentracijama s prekomjernom citotoksičnošću, koje se ne mogu postići u kliničkim uvjetima primjene.
In patients taking rasagiline and/or other medications used to treat Parkinson's disease, the following have been observed: Obsessive thoughts or impulsive behaviour. 
Kod bolesnika koji uzimaju razagilin i/ili druge lijekove koji se koriste za liječenje Parkinsonove bolesti opaženo je sljedeće: Opsesivne misli ili impulzivno ponašanje.
What Rasagiline Mylan is and what it is used for 
Što je Rasagiline Mylan i za što se koristi
Do not stop taking Rasagiline Mylan without first talking to your doctor. 
Ako prestanete uzimati Rasagiline Mylan Nemojte prestati uzimati Rasagiline Mylan prije razgovora sa svojim liječnikom.